Milestone Pharmaceuticals Inc. (MIST) Financial Analysis & Valuation | Quarter Chart
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia i... more
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commerci... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $87.48M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Joseph G. Oliveto |
| IPO Date | 2019-05-09 | CAGR | — |
| Employees | 38 | Website | www.milestonepharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MIST chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $30.46M | P/E | -1.03 | Forward P/E | -0.9 | PEG | — |
| P/S | 0.04 | P/B | 0.01 | P/CF | -0.01 | P/FCF | -0.01 |
| Sales | $2.34M | Sales 1Y | inf% | Sales 3Y | -60.95% | Sales 5Y | -84.38% |
| EPS | $-0.68 | EPS 1Y | -18.82% | EPS 3Y | -49.26% | EPS 5Y | -28.87% |
| Sales QoQ | 134.87% | EPS QoQ | 5% | Sales QoQ Avg | — | EPS QoQ Avg | 5.83% |
| Gross Margin | 94.58% | Operating Margin | -3353.01% | Profit Margin | -3585.62% | ROCE | -49.27% |
| ROA | -46% | ROE | -288% | Altman Z Score | -3.69 | Piotroski Score | 4 |
| Current Ratio | 8.13 | Quick Ratio | 7.92 | Cash Ratio | 7.65 | Op. CF Ratio | — |
| Debt/Equity | 3.3 | Debt/Assets | 0.33 | Lt Debt/Equity | 3.26 | Lt Debt/Cap. | 0.76 |
| Intrst Cov. | -7.27 | Inventory Turnover | 0.03 | Asset Turnover | 0.01 | Receivables Turnover | 0.59 |
| Enterprise Value | $30.46M | P/E Ratio | -1.03 |
| Forward P/E | -0.9 | PEG Ratio | — |
| P/S Ratio | 0.04 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-0.68 | EPS Growth 1Y | -18.82% |
| EPS Growth 3Y | -49.26% | EPS Growth 5Y | -28.87% |
| Revenue Growth 1Y | inf% | Gross Margin | 94.58% |
| Operating Margin | -3353.01% | Profit Margin | -3585.62% |
| ROE | -288% | ROA | -46% |
| ROCE | -49.27% | Current Ratio | 8.13 |
| Quick Ratio | 7.92 | Cash Ratio | 7.65 |
| Debt/Equity | 3.3 | Interest Coverage | -7.27 |
| Altman Z Score | -3.69 | Piotroski Score | 4 |
Milestone Pharmaceuticals Inc. (MIST) valuation & financials
Milestone Pharmaceuticals Inc. (MIST) has a market capitalization of $87.48M and trades at a price-to-earnings ratio of -1.0. It operates in the Healthcare sector (Biotechnology).
Milestone Pharmaceuticals Inc.'s revenue grew — over the last year.
Milestone Pharmaceuticals Inc.'s next earnings report is scheduled for November 11, 2026 (provider scheduled date); analysts estimate EPS of $-0.20. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)